Physician profile
Patrick A Behnke
NPI 1417490772
$54,465.62
in general payments reported to CMS, 2019-2025
30 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $490 · 2022: $6,820 · 2023: $9,281 · 2024: $19K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $12K · Travel and Lodging: $3,497 · Consulting Fee: $1,900 · Education: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,650.00 |
| Food and Beverage | $12,400.53 |
| Travel and Lodging | $3,497.36 |
| Consulting Fee | $1,900.00 |
| Education | $707.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33,986.17 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Galderma Laboratories, L.P. | $6,018.49 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Abbvie INC. | $2,841.33 | 2021-2025 | |
| Ucb, INC. | $2,489.26 | 2022-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,445.06 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,150.97 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $817.23 | 2022-2025 | Sotyktu |
| Pfizer INC. | $780.47 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $648.29 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $631.02 | 2021-2025 | Ilumya, Winlevi |
| Incyte Corporation | $605.08 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $510.62 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $450.54 | 2022-2025 | Dupixent |
| Amgen INC. | $430.40 | 2022-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $288.14 | 2023-2024 | Siliq, Targretin |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $262.11 | 2022-2025 | |
| Genzyme Corporation | $239.71 | 2021-2025 | |
| Almirall LLC | $211.28 | 2022-2024 | Seysara, Klisyri |
| Leo Pharma INC. | $122.77 | 2022-2025 | Adbry, Anzupgo |
| Biofrontera INC. | $122.11 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $118.23 | 2025 | Vtama |
| Epi Health, LLC | $62.97 | 2021-2022 | |
| Kerecis Limited | $43.79 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Botanix Sb INC | $37.74 | 2025 | Sofdra |
| Tactile Systems Technology INC | $37.37 | 2025 | Flexitouch Plus, Nimbl |
| Solta Medical, A Division of Bausch Health US, LLC | $32.53 | 2025 | Clear+Brilliant |
| Revance Therapeutics, INC. | $29.93 | 2025 | Daxxify |
| Strata Skin Sciences, INC. | $23.92 | 2025 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.32 | 2023 | |
| Journey Medical Corporation | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Behnke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.